"With this agreement we add the new therapeutic area of chronic pain management to the Debiopharm product portfolio. There is currently an unmet medical need for the treatment of chronic pain, which can often not be treated successfully and can seriously affect patients' quality of life. For this reason, we have decided to develop this new therapeutic approach," said Rolland-Yves Mauvernay, President and Founder of Debiopharm Group.
"This exclusive licence agreement is very exciting and promising: it will speed up the development of a totally new class of painkillers, hence confirming the validity of our science and chemistry, as well as our capabilities as a drug discovery and early development company," added Thierry Bourbie, Chairman and CEO of Pharmaleads.
Following authorisation from the French Medicine Agency (AFSSAPS), Debio
0827 is about to enter a single ascending dose Phase I, randomised,
double-blind, placebo controlled single oral dose escalation study in
About Neuropathic pain
Neuropathic pain is a major chronic pain condition. According to the most
recent surveys, its estimated prevalence in the world's population is up to
6%, with many causes such as shingles, diabetes, antiviral or antitumor
chemotherapy surgery, or low back disorders. Neuropathic pain does not
respond well to usual painkillers. Worldwide market for neuropathic pain is
estimated to reach
About Debiopharm Group
Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. It develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.
Founded in 1979 and headquartered in
For more information on Debiopharm Group, please visit: http://www.debiopharm.com.
Pharmaleads is a science driven drug discovery and early development
company. Headquartered in
In 2004, Thierry Bourbie, alumnus from Polytechnique and Mines, PhD from
For more information on Pharmaleads, please visit: http://www.pharmaleads.com
Debiopharm S.A. Contacts: Maurice Wagner, Director Corporate Affairs & Communications, Tel.: +41(0)21-321-01-11, Fax: +41(0)21-321-01-69, firstname.lastname@example.org . Additional Media Contacts In London: Maitland, Brian Hudspith, Tel.: +44-(0)20-7379-5151, email@example.com . Jo-Anne Lutjens, Communications Manager, Tel.: +41(0)79-370-27-15, Fax: +41(0)21-321-01-69, firstname.lastname@example.org . In New York: Russo Partners, LLC, Wendy Lau, Tel.: +1-212-845-4272, Fax: +1-212-845-4260, email@example.com . Pharmaleads Contacts: Michel Wurm, Director, Corporate Development, Tel.: +33(0)1-44-06-70-04, Fax: +33(0)1-44-06-60-99, firstname.lastname@example.org . Additional Media Contacts for Pharmaleads: Yucatan, Annie-Florence Loyer, Tel.: +33(0)1-53-63-27-29, email@example.com .
SOURCE The Debiopharm Group